Background: In recent studies, concentrations of cell-free circulating DNA (cf-DNA) have been correlated with clinical characteristics and prognosis in several diseases. The relationship between cf-DNA concentrations and the acute coronary syndrome (ACS) remains unknown. Moreover, no data are available for the detection cf-DNA in ACS by a branched DNA (bDNA)-based Alu assay. The aim of the present study was to investigate cf-DNA concentrations in ACS and their relationship with clinical features. Methods: Plasma cf-DNA concentrations of 137 ACS patients at diagnosis, of 60 healthy individuals and of 13 patients with stable angina (SA) were determined using a bDNA-based Alu assay. Results: ACS patients (median 2,285.0, interquartile range 916.4–4,857.3 ng/ml), especially in ST-segment elevation myocardial infarction patients (median 5,745.4, interquartile range 4,013.5–8,643.9 ng/ml), showed a significant increase in plasma cf-DNA concentrations compared with controls (healthy controls: median 118.3, interquartile range 81.1–221.1 ng/ml; SA patients: median 202.3, interquartile range 112.7–256.1 ng/ml) using a bDNA-based Alu assay. Moreover, we found positive correlations between cf-DNA and Gensini scoring and GRACE (Global Registry of Acute Coronary Events) scoring in ACS. Conclusion: cf-DNA may be a valuable marker for diagnosing and predicting the severity of coronary artery lesions and risk stratification in ACS.

Keywords:
Acute coronary syndrome, Alu, Biomarkers, Branched DNA assay
1.
Mandel P, Metais P: Les acides nucleiques du plasma sanguin chez l’homme. CR Seances Soc Biol Fil 1948;142:241–243.
2.
Fu X, Wan S, Hann HW, Myers RE, Hann RS, Au J, Chen B, Xing J, Yang H: Relative telomere length: a novel non-invasive biomarker for the risk of non-cirrhotic hepatocellular carcinoma in patients with chronic hepatitis B infection. Eur J Cancer 2012;48:1014–1022.
3.
Jylhävä J, Lyytikäinen LP, Kähönen M, Hutri-Kähönen N, Kettunen J, Viikari J, Raitakari OT, Lehtimäki T, Hurme M: A genome-wide association study identifies UGT1A1 as a regulator of serum cell-free DNA in young adults: the Cardiovascular Risk in Young Finns Study. PLoS One 2012;7:e35426.
4.
Lögters T, Paunel-Görgülü A, Zilkens C, Altrichter J, Scholz M, Thelen S, Krauspe R, Margraf S, Jeri T, Windolf J, Jäger M: Diagnostic accuracy of neutrophil-derived circulating free DNA (cf-DNA/NETs) for septic arthritis. J Orthop Res 2009;27:1401–1407.
5.
Stumm M, Entezami M, Trunk N, Beck M, Löcherbach J, Wegner RD, Hagen A, Becker R, Hofmann W: Noninvasive prenatal detection of chromosomal aneuploidies using different next generation sequencing strategies and algorithms. Prenat Diagn 2012;9:1–9.
6.
Chang CP, Chia RH, Wu TL, Tsao KC, Sun CF, Wu JT: Elevated cell-free serum DNA detected in patients with myocardial infarction. Clin Chim Acta 2003;327:95–101.
7.
Shimony A, Zahger D, Gilutz H, Goldstein H, Orlov G, Merkin M, Shalev A, Ilia R, Douvdevani A: Cell free DNA detected by a novel method in acute ST-elevation myocardial infarction patients. Acute Card Care 2010;12:109–111.
8.
Antonatos D, Patsilinakos S, Spanodimos S, Korkonikitas P, Tsigas D: Cell-free DNA levels as a prognostic marker in acute myocardial infarction. Ann NY Acad Sci 2006;1075:278–281.
9.
Federici C, Botto N, Manfredi S, Rizza A, Del Fiandra M, Andreassi MG: Relation of increased chromosomal damage to future adverse cardiac events in patients with known coronary artery disease. Am J Cardiol 2008;102:1296–1300.
10.
Lavon I, Refael M, Zelikovitch B, Shalom E, Siegal T: Serum DNA can define tumor -specific genetic and epigenetic markers in gliomas of various grades. Neuro Oncol 2010;12:173–180.
11.
Schwarzenbach H, Goekkurt E, Pantel K, Aust DE, Stoehlmacher J: Molecular analysis of the polymorphisms of thymidylate synthase on cell-free circulating DNA in blood of patients with advanced colorectal carcinoma. Int J Cancer 2010;127:881–888.
12.
Adrian K, Strouch MJ, Zeng Q, Barron MR, Cheon EC, Honasoge A, Xu Y, Phukan S, Sadim M, Bentrem DJ, Pasche B, Grippo PJ: Tgfbr1 haploinsufficiency inhibits the development of murine mutant Kras-induced pancreatic precancer. Cancer Res 2009;69:9169–9174.
13.
Mosca M, Giuliano T, Cuomo G, Doveri M, Tani C, Curcio M, Abignano G, De Feo F, Bazzichi L, Della Rossa A, Valentini G, Bombardieri S: Cell-free DNA in the plasma of patients with systemic sclerosis. Clin Rheumatol 2009;28:1437–1440.
14.
Jing RR, Wang HM, Cui M, Fang MK, Qiu XJ, Wu XH, Qi J, Wang YG, Zhang LR, Zhu JH, Ju SQ: A sensitive method to quantify human cell-free circulating DNA in blood: relevance to myocardial infarction screening. Clin Biochem 2011;44:1074–1079.
15.
Gensini GG: A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983;51:606.
16.
Fox KA, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O, Avezum A: Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002;23:1177–1189.
17.
Takemura G, Fujiwara H: Role of apoptosis in remodeling after myocardial infarction. Pharmacol Ther 2004;104:1–16.
18.
Boczkowska-Gaik E, Tendera M: Pathogenesis and treatment of acute coronary syndromes (in Polish). Wiad Lek 2005;58:425–432.
19.
Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM: Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999;64:218–224.
20.
GRACE Investigators: Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 2001;141:190–199.
21.
Davì G, Patrono C: Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482–2494.
22.
De Luca G, Verdoia M, Cassetti E, Schaffer A, Cavallino C, Bolzani V, Marino P, Novara Atherosclerosis Study Group (NAS): High fibrinogen level is an independent predictor of presence and extent of coronary artery disease among Italian population. J Thromb Thrombolysis 2011;31:458–463.
23.
Charoensri N, Pornratanarangsi S: D-dimer plasma levels in NSTE-ACS patient. J Med Assoc Thai 2011;94(suppl 1):S39–S45.
24.
Turker Y, Dogan A, Ozaydin M, Kaya S, Onal S, Akkaya M, Erdogan D: Association of thrombotic and fibrinolytic factors with severity of culprit lesion in patients with acute coronary syndromes without ST elevation. South Med J 2010;103:289–294.
25.
Outinen TK, Kuparinen T, Jylhävä J, Leppänen S, Mustonen J, Mäkelä S, Pörsti I, Syrjänen J, Vaheri A, Hurme M: Plasma cell-free DNA levels are elevated in acute Puumala hantavirus infection. PLoS One 2012;7:e31455.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.